Dr. Sipan Mathevosian, MD

Dr. Mathevosian practices at Adventist Health Glendale in Glendale, California, part of Adventist Health.

Dr. Mathevosian's NPI, 1518499722, was assigned on March 28, 2017. Dr. Mathevosian graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2017. Dr. Mathevosian holds California license A157785.

Dr. Mathevosian's primary practice is Adventist Health Glendale, at 1509 E Wilson Terrace, Glendale, CA 91206 in Los Angeles County. The practice phone is (818) 409-8202.

Dr. Mathevosian's primary practice is Adventist Health Glendale in Glendale, California, part of Adventist Health. Dr. Mathevosian is also affiliated with USC Verdugo Hills Hospital. The medical group on file is EVSLA Medical. Dmand AI also links Dr. Mathevosian to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mathevosian practices, 7 sites in all. Vendor and product names are available with a free account.

Diagnostic radiology is Dr. Mathevosian's primary specialty in the NPI Registry, under taxonomy code 2085R0202X. Dr. Mathevosian is board certified in interventional radiology and diagnostic radiology by the American Board of Radiology. Dr. Mathevosian is licensed in California.

CMS data shows 2,499 Medicare services from Dr. Mathevosian across 24 procedure codes in 2024, for 593 Medicare patients. Medicare paid $97,676 for them.

CMS counts 593 Medicare patients who saw Dr. Mathevosian in 2024. The largest group is 65 to 74, with 247 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mathevosian's median patient age at 64, with 51% women.

In 2024, Dr. Mathevosian wrote 20 Medicare Part D claims for 14 patients. 90% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $106 in total drug cost. In 2022, CMS named 20 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Mathevosian for performance year 2024, reported through an alternative payment model (APM). Dr. Mathevosian accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Varicose vein removal: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 87 general payments to Dr. Mathevosian from 19 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 53% of the total. Penumbra, Inc. paid the most, $5,190.

Dr. Mathevosian graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2017.

Dr. Mathevosian is in network with 8 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.